PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph plus ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation.

被引：0

作者：

Cortes, Jorge E.

Kim, Dong-Wook

Pinilla-Ibarz, Javier

Paquette, Ronald

le Coutre, Philipp D.

Chuah, Charles

Nicolini, Franck E.

Apperley, Jane

Khoury, Hanna Jean

Talpaz, Moshe

DiPersio, John F.

DeAngelo, Daniel J.

Rea, Delphine

Abruzzese, Elisabetta

Mueller, Martin C.

Baccarani, Michele

Gambacorti-Passerini, Carlo

Turner, Christopher D.

Haluska, Frank G.

Kantarjian, Hagop

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Catholic Univ Korea, Seoul, South Korea

[3] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

[4] Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA

[5] Charite, D-13353 Berlin, Germany

[6] Singapore Gen Hosp, Singapore, Singapore

[7] Ctr Hosp Lyon Sud, Pierre Benite, France

[8] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, London, England

[9] Emory Winship Canc Inst, Atlanta, GA USA

[10] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[11] Washington Univ, Sch Med, St Louis, MO USA

[12] Dana Farber Canc Inst, Boston, MA 02115 USA

[13] Hop St Louis, Serv Malad Sang, Paris, France

[14] Osped S Eugenio, Rome, Italy

[15] Heidelberg Univ, Med Fak Mannheim, Med Klin 3, Mannheim, Germany

[16] Univ Hosp Bologna, Bologna, Italy

[17] Univ Milano Bicocca, Azienda Osped San Gerardo, Unita Ric Clin Ematol, Monza, Italy

[18] ARIAD Pharmaceut, Cambridge, MA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

6503

引用

页数：2

共 50 条

[41] Asciminib Provides Durable Molecular Responses in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With the T315I Mutation: Updated Efficacy and Safety Data From a Phase I Trial
Hughes, Timothy P.
Cortes, Jorge E.
Rea, Delphine
Mauro, Michael J.
Hochhaus, Andreas
Kim, Dong-Wook
Sasaki, Koji
Lang, Fabian
Heinrich, Michael C.
Breccia, Massimo
Deininger, Michael
Goh, Yeow-Tee
Janssen, Jeroen J. W. M.
Talpaz, Moshe
le Coutre, Philipp
Kapoor, Shruti
Cacciatore, Silvia
Polydoros, Fotis
Agrawal, Nithya
Mahon, Francois-Xavier
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S300 - S300
[42] Dasatinib (BMS-354825) in patients with chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph plus ALL) who are resistant or intolerant to imatinib: Update of a phase I study.
Sawyers, CL
Kantarjian, H
Shah, N
Cortes, J
Paquette, R
Donato, N
Nicoll, J
Bleickardt, E
Chen, TT
Talpaz, M
BLOOD, 2005, 106 (11) : 16A - 16A
[43] Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation
Jiang, Qian
Li, Zongru
Hou, Yue
Hu, Yu
Li, Weiming
Liu, Xiaoli
Xu, Na
Zhang, Yanli
Song, Yongping
Meng, Li
Hong, Zhenya
Liu, Bingcheng
Li, Yan
Chen, Suning
Xue, Mengxing
Zhu, Huanling
Li, He
Du, Xin
Lou, Jin
Zhang, Xiaohan
Liang, Yang
Dai, Yu-Jun
Chen, Zi
Niu, Qian
Men, Lichuang
Yang, Dajun
Zhai, Yifan
Huang, Xiao-Jun
BLOOD, 2022, 140
[44] A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib
Giles, F. J.
le Coutre, P.
Bhalla, K.
Rosti, G.
Ossenkoppele, G.
Alimena, G.
Weitzman, A.
Zheng, M.
Kantarjian, H.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[45] MK-0457, a novel multikinase inhibitor, inhibits BCR-ABL activity in patients with chronic myeloid leukemia (CML) and acute lymphocytic leukemia (ALL) with the t315I BCR-ABL mutation.
Bergstrom, Donald A.
Clark, Jason B.
Xiao, Alan
Griffiths, Matthew
Falcon, Susannah
Pollard, John
Freedman, Steven J.
Giles, Francis
BLOOD, 2006, 108 (11) : 192A - 192A
[46] Multicenter open label study of subcutaneous (SC) omacetaxine (OMA) in imatinib (IM)-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation
Benichou, A.
Khoury, H. J.
Corm, S.
Nicolini, F. E.
Craig, A. R.
Humphriss, E.
Cortes, J. E.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[47] Asciminib Provides Durable Responses and a Favorable Safety Profile in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with the T315I Mutation in a Phase 1 Study
Cortes, Jorge E.
Hughes, Timothy P.
Mauro, Michael J.
Hochhaus, Andreas
Rea, Delphine
Goh, Yeow-Tee
Janssen, J. J. W. M.
Heinrich, Michael C.
Talpaz, Moshe
Etienne, Gabriel
Breccia, Massimo
Deininger, Michael
Le Coutre, Philipp
Lang, Fabian
Polydoros, Fotis
Cacciatore, Silvia
Stenson, Laura
Kim, Dong-Wook
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S335 - S336
[48] Phase II study of dasatinib in children and adolescents with newly diagnosed chronic phase chronic myelogenous leukemia (CP-CML) or Philadelphia-positive (Ph plus ) leukemias resistant or intolerant to imatinib
Rosenberg, J. A.
Derreumaux, D.
Gore, L.
Kearns, P.
Baruchel, A.
Barrett, T.
Zwaan, M.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[49] AIM4CML Trial in Progress: A Phase IIIb Study of Asciminib Monotherapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with and without T315I Mutations
Levy, Moshe Y.
Mauro, Michael J.
Issa, Ghayas C.
Andorsky, David
Tomassetti, Sarah
Maegawa, Rodrigo
Shrestha, Alok
Deininger, Michael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S334 - S335
[50] Additional BCR-ABL1 Mutations Identified By Sensitive Mass Spectrometry In Chronic Phase CML Patients With T315I Treated With Ponatinib Are Associated With Relatively Inferior Responses and Outcome
Parker, Wendy T.
Yeoman, Alexandra L.
Altamura, Haley
Roberts, Nicola
Yeung, David T.
Jamison, Bronte A.
Field, Chani
Lustgarten, Stephanie
Hodgson, Graeme
Rivera, Victor M.
Hughes, Timothy P.
Branford, Susan
BLOOD, 2013, 122 (21)

← 1 2 3 4 5 →